aTyr Pharma IncNASDAQ:LIFE
- LAST PRICE1.7300
- TODAY'S CHANGE (%)-0.0300 (-1.7045%)
- Bid / Lots1.7100/ 10
- Ask / Lots1.8400/ 10
- Open / Previous Close1.7700 / 1.7600
- Day Range
- 52 Week Range
- Volume210,054
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | LIFE |
|---|---|---|
| 09:32 ET | 10005 | 1.76 |
| 09:34 ET | 489 | 1.76 |
| 09:36 ET | 200 | 1.77 |
| 09:41 ET | 400 | 1.78 |
| 09:57 ET | 698 | 1.78 |
| 09:59 ET | 530 | 1.79 |
| 10:03 ET | 100 | 1.78 |
| 10:10 ET | 500 | 1.786 |
| 10:12 ET | 450 | 1.7898 |
| 10:17 ET | 850 | 1.78 |
| 10:21 ET | 1000 | 1.7885 |
| 10:32 ET | 5160 | 1.7801 |
| 10:35 ET | 786 | 1.7747 |
| 10:44 ET | 200 | 1.8 |
| 10:46 ET | 3330 | 1.8 |
| 10:48 ET | 178 | 1.79 |
| 10:50 ET | 1200 | 1.8 |
| 10:51 ET | 224 | 1.8 |
| 10:53 ET | 171 | 1.785 |
| 10:57 ET | 181 | 1.785 |
| 11:04 ET | 168 | 1.785 |
| 11:06 ET | 2184 | 1.785 |
| 11:11 ET | 26840 | 1.845 |
| 11:13 ET | 2000 | 1.845 |
| 11:15 ET | 2714 | 1.85 |
| 11:18 ET | 150 | 1.85 |
| 11:20 ET | 2640 | 1.86 |
| 11:22 ET | 1812 | 1.85 |
| 11:24 ET | 2895 | 1.855 |
| 11:26 ET | 1400 | 1.84 |
| 11:27 ET | 1415 | 1.85 |
| 11:29 ET | 200 | 1.86 |
| 11:31 ET | 2500 | 1.85 |
| 11:36 ET | 3778 | 1.85 |
| 11:40 ET | 2400 | 1.85 |
| 11:45 ET | 3800 | 1.85 |
| 11:47 ET | 981 | 1.855 |
| 11:51 ET | 6100 | 1.855 |
| 11:54 ET | 1600 | 1.8501 |
| 11:56 ET | 5384 | 1.85 |
| 11:58 ET | 5495 | 1.855 |
| 12:00 ET | 5738 | 1.8401 |
| 12:09 ET | 12660 | 1.82 |
| 12:12 ET | 6100 | 1.8 |
| 12:16 ET | 500 | 1.8 |
| 12:25 ET | 1000 | 1.8099 |
| 12:34 ET | 6046 | 1.8 |
| 12:36 ET | 700 | 1.79 |
| 12:43 ET | 100 | 1.78 |
| 01:01 ET | 200 | 1.8 |
| 01:06 ET | 1600 | 1.795 |
| 01:08 ET | 2100 | 1.795 |
| 01:12 ET | 230 | 1.8 |
| 01:14 ET | 13043 | 1.7515 |
| 01:17 ET | 900 | 1.75 |
| 01:19 ET | 100 | 1.75 |
| 01:24 ET | 100 | 1.77 |
| 01:37 ET | 100 | 1.779 |
| 01:39 ET | 1000 | 1.7799 |
| 01:44 ET | 105 | 1.77 |
| 01:46 ET | 1000 | 1.7699 |
| 01:50 ET | 400 | 1.78 |
| 01:57 ET | 645 | 1.774 |
| 02:06 ET | 200 | 1.775 |
| 02:29 ET | 5947 | 1.75 |
| 02:40 ET | 500 | 1.7593 |
| 02:45 ET | 2000 | 1.74 |
| 02:47 ET | 100 | 1.73 |
| 02:56 ET | 200 | 1.7485 |
| 02:58 ET | 984 | 1.744 |
| 03:02 ET | 600 | 1.745 |
| 03:03 ET | 800 | 1.745 |
| 03:07 ET | 7126 | 1.735 |
| 03:09 ET | 1597 | 1.7294 |
| 03:12 ET | 1045 | 1.725 |
| 03:14 ET | 300 | 1.72 |
| 03:16 ET | 1000 | 1.7229 |
| 03:18 ET | 1490 | 1.72 |
| 03:20 ET | 600 | 1.73 |
| 03:23 ET | 415 | 1.725 |
| 03:25 ET | 200 | 1.725 |
| 03:30 ET | 2492 | 1.72 |
| 03:32 ET | 400 | 1.715 |
| 03:34 ET | 1300 | 1.71 |
| 03:36 ET | 600 | 1.715 |
| 03:41 ET | 200 | 1.715 |
| 03:45 ET | 900 | 1.73 |
| 03:48 ET | 100 | 1.725 |
| 03:52 ET | 3700 | 1.725 |
| 03:54 ET | 100 | 1.725 |
| 03:57 ET | 716 | 1.725 |
| 03:59 ET | 572 | 1.73 |
May 24, 2024
aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4), from 4:00PM ET on Friday May 24, 2024 by Dow Jones
4:00PM ET on Friday May 24, 2024 by Dow Jones
May 15, 2024
aTyr Pharma to Present Poster Describing Efzofitimod's Mechanism of Action at the American Thoracic Society 2024 International Conference, from 7:00AM ET on Wednesday May 15, 2024 by Dow Jones
7:00AM ET on Wednesday May 15, 2024 by Dow Jones
May 14, 2024
DJ aTyr Pharma Price Target Maintained With a $35.00/Share by HC Wainwright & Co., from 11:03AM ET on Tuesday May 14, 2024 by Dow Jones
11:03AM ET on Tuesday May 14, 2024 by Dow JonesaTyr Pharma Announces Second Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT(TM) Study in Pulmonary Sarcoidosis, from 8:00AM ET on Tuesday May 14, 2024 by Dow Jones
8:00AM ET on Tuesday May 14, 2024 by Dow Jones
May 6, 2024
aTyr Pharma to Present at Upcoming Investor Conferences, from 8:00AM ET on Monday May 06, 2024 by Dow Jones
8:00AM ET on Monday May 06, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
aTyr Pharma Inc | 119.4M | -1.9x | --- |
Vigil Neuroscience Inc | 119.5M | -1.5x | --- |
Adicet Bio Inc | 119.2M | -0.5x | --- |
Nuvectis Pharma Inc | 124.3M | -4.8x | --- |
Citius Pharmaceuticals Inc | 126.0M | -2.9x | --- |
Immunic Inc | 111.7M | -0.7x | --- |
Company Information
aTyr Pharma, Inc. is a clinical-stage biotechnology company. The Company is leveraging intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation. Its lead therapeutic candidate is efzofitimod, a biologic immunomodulator in clinical development for the treatment of interstitial lung disease (ILD), a group of immune-mediated disorders that can cause inflammation and fibrosis, or scarring, of the lungs. Efzofitimod is a tRNA synthetase derived therapy that selectively modulates activated myeloid cells through neuropilin-2 (NRP2) to resolve aberrant inflammation without immune suppression and prevent the progression of fibrosis. ATYR0101 is a fusion protein derived from a domain of aspartyl-tRNA synthetase (DARS). ATYR0101 binds directly to latent-transforming growth factor beta-binding protein 1 (LTBP1), which regulates transforming growth factor beta (TGFb). Its ATYR0750 is a fusion protein derived from a domain of alanyl-tRNA synthetase (AARS).
Contact Information
- Headquarters
- 10240 Sorrento Valley Road, Suite 300SAN DIEGO, CA, United States 92121
- Phone
- 858-731-8389
- Fax
- 858-731-8394
Executives
- Independent Chairman of the Board
- John Clarke
- President, Chief Executive Officer, Director
- Sanjay Shukla
- Chief Financial Officer
- Jill Broadfoot
- General Counsel, Corporate Secretary
- Nancy Denyes
- Independent Director
- Timothy Coughlin
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $119.4M |
|---|---|
Revenue (TTM) | $588.0K |
Shares Outstanding | 69.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.19 |
EPS | $-0.90 |
Book Value | $1.43 |
P/E Ratio | -1.9x |
Price/Sales (TTM) | 203.0 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -9,994.56% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
